On Apr. 21, 2020, BioSig Technologies announced that subsidiary ViralClear Pharmaceuticals, had submitted an application for Vicromax(tm) (merimepodib, or MMPD) through the U.S. Food and Drug Administration (FDA’s) Coronavirus Treatment Acceleration Program (CTAP) to administer the drug to hospitalized patients with COVID-19.